SEARCH

SEARCH BY CITATION

References

  • 1
    Armstrong TD, Clements VK, Ostrand-Rosenberg S. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo. J Immunother 1998; 21: 21824.
  • 2
    Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003; 46: 3357.
  • 3
    Zeh HJ, Stavely-O’Carroll K, Choti MA. Vaccines for colorectal cancer. Trends Mol Med 2001; 7: 30713.
  • 4
    Mayer L, Eisenhardt D, Salomon P, Bauer W, Plous R, Piccinini L. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 1991; 100: 312.
  • 5
    Satoh A, Toyota M, Ikeda H et al. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 2004; 23: 887686.
  • 6
    Matsushita K, Takenouchi T, Kobayashi S et al. HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-γin situ and its association with tumour progression. Br J Cancer 1996; 73: 6448.
  • 7
    Ishii N, Chiba M, Iizuka M, Horie Y, Masamune O. Induction of HLA-DR antigen expression on human colonic epithelium by tumor necrosis factor-α and interferon-γ. Scand J Gastroenterol 1994; 29: 9037.
  • 8
    Lovig T, Andersen SN, Thorstensen L et al. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer 2002; 87: 75662.
  • 9
    Andersen SN, Rognum TO, Lund E, Meling GI, Hauge S. Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis. Br J Cancer 1993; 68: 805.
  • 10
    Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 1987; 166: 122944.
  • 11
    Dredge K, Marriott JB, Todryk SM, Dalgleish AG. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 2002; 51: 52131.
  • 12
    Ramana CV, Grammatikakis N, Chernov M et al. Regulation of c-myc expression by IFN-γ through Stat1-dependent and -independent pathways. EMBO J 2000; 19: 26372.
  • 13
    Carlberg AL, Moberg KH, Hall DJ. Tumor necrosis factor and gamma-interferon repress transcription from the c-myc P2 promoter by reducing E2F binding activity. Int J Oncol 1999; 15: 1216.
  • 14
    Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109: 32134.
  • 15
    Secombe J, Pierce SB, Eisenman RN. Myc: a weapon of mass destruction. Cell 2004; 117: 1536.
  • 16
    Muto T, Kotake K, Koyama Y. Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. Int J Clin Oncol 2001; 6: 1716.
  • 17
    Imaseki H, Hayashi H, Taira M et al. Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. Cancer 1989; 64: 7049.
  • 18
    Murphy SP, Choi JC, Holtz R. Regulation of major histocompatibility complex class II gene expression in trophoblast cells. Reprod Biol Endocrinol 2004; 2: 529.
  • 19
    Kanaseki T, Ikeda H, Takamura Y et al. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J Immunol 2003; 170: 49805.
  • 20
    Hershberg RM, Cho DH, Youakim A et al. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells. J Clin Invest 1998; 102: 792803.
  • 21
    Diederichsen AC, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52: 4238.
  • 22
    Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 20313.
  • 23
    Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. Apmis 1995; 103: 16179.
  • 24
    Ishigami S, Natsugoe S, Tokuda K et al. CD3-zetachain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 2002; 94: 143742.
  • 25
    Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91: 213647.
  • 26
    Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 9918.
  • 27
    Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95109.
  • 28
    Sato K, Miyahara M, Saito T, Kobayashi M. c-myc mRNA overexpression is associated with lymph node metastasis in colorectal cancer. Eur J Cancer 1994; 30A: 111317.
  • 29
    Nagy B, Lundan T, Larramendy ML et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is a poor prognostic sign in mantle cell lymphoma. Br J Haematol 2003; 120: 43441.
  • 30
    Shachaf CM, Kopelman AM, Arvanitis C et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; 431: 111217.